ResMed Q3 FY2023 revenue +29% to $1.12B; EPS $1.58, non-GAAP $1.68

RESMED INC

2023-Q3 EPS reported $4.53 revenue$3,100,936,000

Revenue $1,116.9M, up 29% YoY (31% constant currency); diluted EPS $1.58, non-GAAP $1.68.
Operating income +28% to $300.7M; non-GAAP operating income +27% to $321.2M.
Gross margin contracted 150 bps to 55.3%; non-GAAP gross margin down 200 bps to 56.1%.
CEO: full global availability of AirSense 10; ramping AirSense 11; strong mask and SaaS growth.
Quarterly dividend $0.44/share declared; payable June 15, record May 11.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RESMED INC reported the quarter ended March 31, 2023 results: revenue $1,116.9 million, EPS $1.58.

Period: the quarter ended March 31, 2023
Revenue: $1,116.9 million
EPS: $1.58
Result: reported results

Exact text from the filing

ASX: RMD) today announced results for its quarter ended March 31, 2023. Third Quarter 2023 Highlights All comparisons are to the prior year period • Revenue increased by 29% to $1,116.9 million; up 31% on a constant currency basis • Gross margin contracted 150 bps to 55.3%; non-GAAP gross margin contracted 200 bps to 56.1% • Income from operations increased 28%;

View on SEC.gov

Browse all earnings releases →

RESMED INC filing history →

Source: SEC EDGAR

accession 0001193125-23-122110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.